Department of Analysis, Hospital de Especialidades Teodoro Maldonado Carbo, Guayaquil, Ecuador
Review Article
Effectiveness of VIUSID® and ASBRIP® in Hospitalized Patients Infected by SARS-CoV-2 and Mild-to-Moderate Respiratory Illness. An Observational Prospective Study
Author(s): Wilson I Benites*, Martha V Heras, Mario L Mero and David Marquez
Background: The emerging SARS-CoV-2 infection has been associated with moderate and severe disease in patients with a weaker cellular immunity which might result in prolonged period of hospitalizations. Viusid® has shown recognized immunoregulator properties, including an important modulation on IFN-δ, TNF-α, IL-1β and IL-6 levels in patients with infectious diseases. Our observational study was aimed to evaluate the effectiveness of Viusid® along with Asbrip®, an upper respiratory antiseptic, in patients with mild to moderate symptoms related with SARS-COV-2 infection.
Methods: An observational study was conducted to evaluate the efficacy of Viusid and Asbrip® in patients with mild to moderate symptoms of respiratory disease caused by the emerging SARS-CoV-2 infectio.. Read More»
DOI:
10.37421/2684-4559.2021.5.145
Clinical Infectious Diseases: Open Access received 49 citations as per Google Scholar report